Search

Arcutis Biotherapeutics Inc

Suletud

SektorTervishoid

23.51 -3.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.82

Max

24.73

Põhinäitajad

By Trading Economics

Sissetulek

26M

15M

Müük

24M

130M

P/E

Sektori keskmine

108.636

56.597

Aktsiakasum

0.11

Kasumimarginaal

11.558

Töötajad

354

EBITDA

23M

17M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+53.11% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

27. okt 2026

Turustatistika

By TradingEconomics

Turukapital

-241M

3B

Eelmine avamishind

26.64

Eelmine sulgemishind

23.51

Uudiste sentiment

By Acuity

44%

56%

97 / 339 Pingereas Healthcare

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. sept 2026, 20:02 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing, having rebounded from an early session low amid broader market concerns over rising crude oil prices.

11. sept 2026, 19:46 UTC

Arcutis Biotherapeutics is gaining today, reaching earlier highs amid broader market reactions to Consumer Price Index data and interest rate speculation.

10. sept 2026, 23:06 UTC

Arcutis Biotherapeutics shares are lower in after-market hours, continuing a downward trend observed over the past three sessions. The price remains below the 20-day moving average.

9. sept 2026, 19:26 UTC

Arcutis Biotherapeutics is declining amid broader market pressure from rising crude oil prices, which reached $100.49 per barrel during Wednesday's session.

8. sept 2026, 23:41 UTC

Arcutis Biotherapeutics shares rose in after-market trading, marking a shift from the recent trend of higher daily closes since Tuesday's close.

4. sept 2026, 20:07 UTC

News

Arcutis Biotherapeutics granted 57,000 RSUs to new employees, supporting growth initiatives. Shares are higher since Thursday's close despite a pullback earlier in the session.

1. sept 2026, 20:01 UTC

Arcutis Biotherapeutics Inc. shares are lower today, trading significantly below the 20-day moving average amid rising oil prices and inflation concerns.

31. aug 2026, 19:36 UTC

Arcutis Biotherapeutics Inc shares are higher today, recovering from earlier losses despite no specific news to explain the price movement.

28. aug 2026, 22:56 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, though no specific news was identified. Broader market conditions may influence this movement.

26. aug 2026, 20:08 UTC

Arcutis Biotherapeutics Inc shares are higher Wednesday, pulling back from session highs. Broader market fluctuations follow inflation data indicating rising consumer prices.

25. aug 2026, 19:36 UTC

News

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

24. aug 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

21. aug 2026, 19:56 UTC

Event

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

20. aug 2026, 19:51 UTC

News

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

19. aug 2026, 19:26 UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

18. aug 2026, 19:56 UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

14. aug 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13. aug 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12. aug 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11. aug 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10. aug 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7. aug 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6. aug 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5. aug 2026, 23:02 UTC

News
Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4. aug 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3. aug 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31. juuli 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30. juuli 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29. juuli 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28. juuli 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

53.11% tõus

12 kuu keskmine prognoos

Keskmine 36.571 USD  53.11%

Kõrge 40 USD

Madal 34 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

97 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat